PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with ...

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported ...

Moby Strategic Execution and Safety Management. Management attributes the 2025 performance to rapid enrollment in the H ...

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

Ontario family speaks out after son's controversial euthanasia under Canada's MAID laws, alleging system failed to protect ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Demyelinating diseases, including multiple sclerosis (MS) and Charcot-Marie-Tooth (CMT) disease, present a substantial and escalating burden. | Demyelinating diseases, including multiple sclerosis (MS ...

Results from ADAPT OCULUS are expected to support a sBLA submission to the FDA to secure a label expansion for oMG.

Learn more about whether Celldex Therapeutics, Inc. or Zai Lab Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

NORTHAMPTON, Mass. (WWLP) – A patient at Cooley Dickinson Hospital in Northampton is showcasing her paintings during a solo ...

International equities added another 5% in the fourth quarter, finishing up more than 30% for the year, the largest gain ...